ClinicalTrials.gg

Program

ONO-1110

A development code.

Its studies are mostly in Neuralgia, Postherpetic · Phobia, Social · Depressive Disorder, Major · Fibromyalgia · Cystitis, Interstitial, led by Ono Pharmaceutical.

Furthest: phase 2, since Nov 24, 20245 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceutical50 open or runningphase 2since Nov 24, 2024Nov 24, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2024First study: phase 2 study in Neuralgia, PostherpeticFirst studyNCT06708416 · 142 enrolled · Japan
  2. Dec 22, 20242 phase 2 studiesNCT06752603, NCT06752590
  3. Jan 19, 20252 phase 2 studiesNCT06792136, NCT06805565

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06805565Phobia, Social · Japan2CompletedMay 25, 2026115
NCT06792136Depressive Disorder, Major · Japan2CompletedApr 9, 2026103
NCT06752603Hunner Type Interstitial Cystitis · Japan2CompletedJun 12, 202657
NCT06752590Fibromyalgia · Japan2CompletedMay 30, 2026175
NCT06708416Neuralgia, Postherpetic · Japan2CompletedMay 11, 2026142

How it is read

Names in the registry

  • “ONO-1110”, 5 entries

Codes read as this program: ONO1110.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.